Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA - Free Report) in a research report released on Thursday morning,Benzinga reports. The firm currently has a $14.00 price objective on the stock.

Separately, D. Boral Capital restated a "buy" rating and set a $18.00 price objective on shares of Coya Therapeutics in a research report on Tuesday, March 18th.

Coya Therapeutics Stock Down 0.4 %

Shares of NASDAQ:COYA traded down $0.03 during trading on Thursday, reaching $6.65. 37,261 shares of the company's stock traded hands, compared to its average volume of 71,194. The firm has a market cap of $111.22 million, a PE ratio of -10.23 and a beta of 0.31. Coya Therapeutics has a fifty-two week low of $4.75 and a fifty-two week high of $10.24. The company has a 50-day simple moving average of $6.34 and a 200-day simple moving average of $6.50.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.14. The business had revenue of $0.20 million during the quarter, compared to analysts' expectations of $0.10 million. On average, equities research analysts forecast that Coya Therapeutics will post -1.15 EPS for the current year.

Remove Ads

Hedge Funds Weigh In On Coya Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in COYA. AIGH Capital Management LLC raised its stake in Coya Therapeutics by 85.0% in the 4th quarter. AIGH Capital Management LLC now owns 1,201,152 shares of the company's stock valued at $6,883,000 after purchasing an additional 551,725 shares during the last quarter. DME Capital Management LP grew its holdings in shares of Coya Therapeutics by 29.2% during the fourth quarter. DME Capital Management LP now owns 1,646,440 shares of the company's stock worth $9,434,000 after buying an additional 372,414 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in shares of Coya Therapeutics in the fourth quarter valued at about $401,000. CM Management LLC lifted its stake in shares of Coya Therapeutics by 11.1% in the fourth quarter. CM Management LLC now owns 160,000 shares of the company's stock worth $917,000 after buying an additional 15,941 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in Coya Therapeutics during the fourth quarter worth about $74,000. Hedge funds and other institutional investors own 39.75% of the company's stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.